The effect of empagliflozin on kidney function: results from the EMPEROR-Reduced trial

Watch the discussion between Professor Andrew Coats and Professor Javed Butler reviewing cardiovascular and kidney outcomes from the EMPEROR-Reduced Phase III trial. This study looks at the association between empagliflozin and improved cardiovascular outcomes in heart failure patients with reduced ejection fraction (HFrEF), with and without diabetes, and with and without chronic kidney disease.

Topic

The EMPEROR-Reduced trial is a phase III randomised, double-blind trial that aims to evaluate the efficacy and safety of once-daily empagliflozin compared with placebo in 3,730 patients with chronic heart failure with HFrEF, with and without diabetes mellitus (DM). This 30-minute journal club will explore the efficacy and safety of empagliflozin across the spectrum of kidney function in heart failure patients with HFrEF from the results of the EMPEROR-Reduced trial.

Target audience

This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in heart failure management.

Learning objectives

• Recall the efficacy and safety of empagliflozin on cardiac and renal outcomes in patients with HFrEF and impaired kidney function
• Describe why empagliflozin has a salutary effect on renal outcomes and how this compares to other SGLT2 inhibitors, such as dapagliflozin
• Explain the clinical implications of treating heart failure patients with kidney impairment, with and without DM2

Accreditation

”The effect of empagliflozin on kidney function: results from the EMPEROR-Reduced trial’ – live webinar’ has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 1 category 1 (external) CPD credit(s).